Synergistic preparation for treating urinary tract inflammation, e.g. cystitis, contains low molecular hyaluronic acid and another glycosaminoglycan, preferably chondroitin sulfate

摘要

A pharmaceutical preparation (I) contains effective amounts of (a) hyaluronic acid and/or its salts (preferably of average molecular weight less than 200 kDa) and (b) other glycosaminoglycan(s) (preferably chondroitin sulfate(s)). ACTIVITY : Antiinflammatory; Uropathic. A composition containing sodium hyaluronate (a') of non-animal origin (average molecular weight 180 kDa) and chondroitin sulfate (b') of marine origin (each at 40 mg per 50 ml) was instilled into the bladder of interstitial cystitis patients once per week for 2 months. The average subjective effectiveness at the end of the therapy (on a scale of 1 = very good to 6 = inadequate) was 2.0, compared with 3.1 after treatment with (a') only, 3.3 after treatment with (b') only and 4.8 after placebo treatment. Cytoscopic studies showed that in the group treated with both (a') and (b') the bladder mucosa was almost completely intact, with no lesions or bleeding. MECHANISM OF ACTION : Protection, reduction of permeability and regeneration of urinary tract mucosa.